Intellia Therapeutics, Inc.
NTLA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,153 | $2,707 | $2,686 | $8,383 |
| - Cash | $189 | $227 | $524 | $123 |
| + Debt | $210 | $115 | $131 | $74 |
| Enterprise Value | $1,174 | $2,595 | $2,293 | $8,333 |
| Revenue | $58 | $36 | $52 | $33 |
| % Growth | 59.6% | -30.4% | 57.7% | – |
| Gross Profit | $48 | $27 | $45 | $26 |
| % Margin | 82.2% | 75.3% | 85.5% | 79.2% |
| EBITDA | -$524 | -$506 | -$451 | -$261 |
| % Margin | -905.3% | -1,395.8% | -864.5% | -789.5% |
| Net Income | -$519 | -$481 | -$474 | -$268 |
| % Margin | -896.8% | -1,326.5% | -909.8% | -810.5% |
| EPS Diluted | -5.25 | -5.42 | -6.16 | -3.78 |
| % Growth | 3.1% | 12% | -63% | – |
| Operating Cash Flow | -$349 | -$394 | -$333 | -$225 |
| Capital Expenditures | -$6 | -$14 | -$58 | -$13 |
| Free Cash Flow | -$355 | -$408 | -$392 | -$238 |